Arcadia Biosciences, Inc. (RKDA): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Arcadia Biosciences, Inc. (RKDA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K 0001469443 false 0001469443 2026-07-01 2026-07-01 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 01,
How this was made
The 30-second read
Why it matters
Board/Compensation Committee approved a discretionary cash bonus for Schaefer for 2025 on July 1, 2026, and the 8-K updates the 2025 Summary Compensation Table accordingly.
Market read
This is a governance/compensation update rather than a new business milestone; it mainly affects executive compensation accounting disclosures.
What to watch
The 8-K also references a terminated proposed business combination (Roosevelt Resources, LP) as a reason no plan bonuses were paid for 2025; however, the termination itself is not newly disclosed here.
Background
The company previously filed a 10-K/A footnote stating the 2025 bonus amount for CEO Thomas J. Schaefer was not determinable at the time of filing, with an 8-K to follow once determined.
Ticker impact
Arcadia Biosciences disclosed a discretionary 2025 cash bonus for CEO/Interim CFO Thomas J. Schaefer via Item 5.02 of an 8-K.
Limited near-term impact; any reaction is likely small and sentiment-driven rather than fundamental.
This is an SEC 8-K compensation disclosure tied to a previously noted determinability footnote in the 10-K/A, not an operational or financial guidance change.
Market effects
Minimal; executive compensation mechanics typically do not reset sector expectations.
Minimal; company-specific governance/compensation disclosure.
Minimal; no cross-border deal, regulation, or product event disclosed.
Counterpoint
Traders may overreact to executive compensation headlines, but the disclosure is largely administrative—confirming a bonus amount that was previously flagged as not determinable.
Key entities
- companyArcadia Biosciences, Inc.
Nasdaq-listed biotech company filing an 8-K to disclose discretionary executive bonus compensation and related director/shareholder meeting timing.
- executiveThomas J. Schaefer
CEO and Interim CFO; received a discretionary cash bonus for 2025, with updated compensation table totals.
- executiveMark Kawakami
Former CFO; resigned effective September 12, 2025; options expired/terminated per the filing.
